Member Info for MCB55

Av6000 was materially derisked when Safety Committee approved a DE of 50%. In other words the science safely works in humans, a major inflexion point! I accept that early days yet, but NO significant safety issues after 6 months is a great indicator! The trial will be monitoring every indicator you can imagine, from blood samples to physical (I am not a medic)and nothing has shown up as significantly negative. As Fiona says they are currently analysing biopsies on the tumours. Result of that will be significant!

Buying begets buying!

gmcc
"POINT’s CanSEEK™ has been sub-licensed from both Bach Biosciences and Avacta Life Sciences, who has branded the technology as pre|CISION™(an Avacta trademark)."
So why isn't Avacta publicising this today!? We need any bit of good news we can!

Once the rise begins it will grow n grow!

Will AS release the results of the tumour biopsies, at least in principle!? That would be a major rns!

Runner, yes I am with you, this is surely the bottom!

If all the "fly by nighters" have flown then who keeps selling keeping the sp down.....must be many more to go yet!

"Who knows what will happen next 6-8 months not much point worrying about it."
I agree no point worrying, HOWEVER a CEO is supposed to set out his plan for the short/medium and long term vision. AS seems to be wary of that!!

I agree the LFT is not dead and it shouldn't be either, if only to maintain credibility for now and the future! A team in Yorkshire will be on it in a big way, its just that AS did not exactly bull up the near success (still looking for antibody and who knows reaction of Regulators......a CEO can spin these better without lying!).

It also means that even at the current 90% of standard dose with little side effects it is very much better than normal treatment!

Thanks Pier6!
Not clear why AS wouldn’t have explained this because it means a lot to the layman that first 3 patients have little to no side effects/ toxicity! Does he think it is unethical / not appropriate, is he constrained by medical protocol!? I know 3 patients is not a .statistically significant, but even so it is all pointing in the right direction.

Slide 10 says 4 patients dosed in cohort 1 and also likely 4 cohorts to achieve MTD.

Certainly hope so!

There is panic for II’s to buy just yet, they can take their time as no inflexion point for 5 mths, unless the sp steadily creeps up after this initial hit!?

Both AS & Fiona are first and foremost biochemists, the world of PR/Finance/shareholders interests is somewhat alien to them! AS knows a bit, as that's his job, however he is not charmer, and its good he doesn't deliberately tell lies (imo) unlike some CEO's. Fiona knows her technical stuff, but seems somewhat unaware of what turns on shareholders, like when is the next inflexion point (she was saying end of Ph1/ mid 2023 and AS had to bring it back to end of Ph1a mid this year!).

If I remember right Trinity valued the therapeutics arm/precision platform at £2.2; that is with no value to diagnostics, and this was based on risked NPV with a confidence level of about 10%. We must have derisked quite a bit given the Av6000 success to date (although we don’t know the details) so I would suggest that chance of success must now be vastly improved to at least double, 20% and £4.4, and probably more like 30-50% given this first hurdle of safety in humans is so critical/ fundamental!
I wonder if Trinity will update their analysis?

Ophidian,
"I have my own views on what was actually being said about the LFD which I will not share here but I wouldn't write it off too soon."
I certainly hope you are right, some early positive news on LFT would support the sp in the near term!

I think that AS is a bit too honest, he is not very upbeat about LFT update/reg approvals and timescales and puts all his weight on shareholder value on the cancer side, for which the only major inflexion point now is mid year. However there must be some interim news on US first dosing, etc.

Maybe last weeks II's will start buying this week, a few million or so might just do the trick!?

The sp needs a good push above £1, that will squeeze the shorters and provide another push!